Infections represent a serious threat to the successful utilization of implants in modern medicine. Implant-associated infections are difficult to treat, because they involve biofilms that protect bacteria from the immune system and harbour antibiotic-tolerant persister cells. In this work, we developed an antibody-drug conjugate (ADC) containing the anti-neoplastic drug mitomycin C (MMC) as a novel treatment paradigm for implant-associated infections. MMC was chosen as it is a potent antimicrobial against biofilms and its synthesis into an ADC was chosen to alleviate toxicity. Following development and synthesis of the ADC, stability and release of MMC was measured. We then used the ADC to kill bacteria in suspension and in biofilms, Mitomycin C was conjugated to a commercially available antibody against ADC as tested against Finally, two independent Aim
Method
A bone abscess in the distal femoral metaphysis of an eighteen years old girl is described which was found to have been caused by bacterium coli sensitive to chloromycetin only. Surgical treatment combined with local administration of chloromycetin promptly cured the lesion.
